The National Institute for Health and Care Excellence (NICE) have published new or updated guidance for the month of September 2021. This month is one technology appraisal and one COVID-19 rapid guideline that impact upon primary care.
The Sapropterin for treating hyperphenylalaninaemia in phenylketonuria technology appraisal has been published. This treatment is recommended as an option for treating hyperphenylalaninaemia that responds to sapropterin (response as defined in the summary of product characteristics) in people with phenylketonuria (PKU), only if they are:
- under 18 and a dose of 10 mg/kg is used, only using a higher dose if target blood phenylalanine levels cannot be achieved at 10 mg/kg
- aged 18 to 21 inclusive, continuing the dose they were having before turning 18 or at a maximum dose of 10 mg/kg
- pregnant (from a positive pregnancy test until birth).
It is also noted that sapropterin is recommended only if the company provides it according to the commercial arrangement. It would be expected that treatment would be commenced and supervised by a specialist.
The COVID-19 rapid guideline: managing COVID-19 guideline has been updated. The update this month adds new recommendations on non-invasive respiratory support and doxycycline, and updated recommendations on heparins. Specifically for primary care it is recommended that doxycycline is not used to treat COVID-19 in the community.
Action: Clinicians should be aware of this month's new guidance and implement any necessary changes to practice.
|« Drug Safety Update - September 2021||CKS Updates - September 2021 »|